Loading
A phase 3 trial testing SHR-1501 in bladder & urothelial cancer, now recruiting.
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC is a phase 3 interventional study registered as NCT07424287, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Multicenter, Randomised, Open-label Phase III Clinical Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Investigator-selected Chemotherapy In Patients With BCG-unresponsive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC) (NiBladder 1). Planned enrolment is 236 participants (estimated). The study started in 2026-07-13 and primary completion is expected in 2030-06. No results have been posted on ClinicalTrials.gov.
Shares SHR-1501, Non-muscle-invasive bladder cancer, Jiangsu Hengrui Pharmaceuticals, Bladder & urothelial cancer.
Shares SHR-1501, Jiangsu Hengrui Pharmaceuticals.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.